Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 11/20 | 0.80 |
| ▸ | RET | P07949 | 5/20 | 0.55 |
| ▸ | JAK2 | O60674 | 4/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | HCK | P08631 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 3/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7506714 | 0.89 | SRC (1.00) | SRCJAK2ABL1HCKJAK3 | |
| SCHEMBL7513391 | 0.82 | SRC (1.00) | SRCRETABL1HCK | |
| SCHEMBL14982754 | 0.80 | SRC (0.65) | SRCRETABL1HCK | |
| SCHEMBL7520883 | 0.76 | SRC (1.00) | SRCABL1HCK | |
| SCHEMBL14982739 | 0.75 | SRC (0.77) | SRCRETABL1HCK | |
| SCHEMBL7515173 | 0.74 | SRC (0.76) | SRCRETABL1HCK | |
| SCHEMBL16572731 | 0.74 | SRC (0.75) | SRCRETABL1HCK | |
| SCHEMBL12120704 | 0.74 | SRC (0.75) | SRCABL1HCK | |
| SCHEMBL7509503 | 0.74 | SRC (1.00) | SRCRETABL1HCK | |
| SCHEMBL12068730 | 0.73 | SRC (1.00) | SRCRETABL1HCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353116-B2 | Methods and compositions for kinase inhibition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353116-B2 | Methods and compositions for kinase inhibition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353116-B2 | Methods and compositions for kinase inhibition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-31 | — | — | US | disclosed |
| US-20130137708-A1 | METHODS AND COMPOSITIONS FOR KINASE INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137708-A1 | METHODS AND COMPOSITIONS FOR KINASE INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137708-A1 | METHODS AND COMPOSITIONS FOR KINASE INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137708-A1 | METHODS AND COMPOSITIONS FOR KINASE INHIBITION | SRC, ABL1, LCK | SRC 1/4885RET 120/4885JAK2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.